Agentic vs Manual Healthcare Pentesting: Safety and Evidence First

Evaluate the testing system, not the word agentic

Agentic healthcare penetration testing should be evaluated by the actions it can take, the authority it holds, the evidence it produces and the human decisions that constrain it. The label does not establish safety, depth or accuracy. A system that proposes tests for a reviewer is materially different from one that executes tools against live infrastructure without approval. Procurement should make that distinction explicit.

This guide helps healthcare teams compare automated, agent-assisted and manual assessment approaches. It does not argue that all automation is unsafe or that human testing is automatically thorough. Both can fail. The objective is to choose a controlled combination that answers the organisation’s security questions while respecting clinical operations and sensitive information.

Use the questions below when scoping healthcare penetration testing. The examples are hypothetical planning scenarios, not claims about a named product or a completed engagement. Any active test requires permission for the target, technique and timing. An AI-generated plan does not expand the authority granted to the assessment team.

Separate automation, assistance and delegated action

Conventional automation performs a defined sequence or check. An assistant may summarise evidence, suggest a next step or help an assessor organise findings. An agent may choose and execute tools based on observations and a goal. Real products can combine these patterns, so ask the provider to describe the actual workflow rather than assigning it a category from marketing language.

The distinction matters because dynamic tool selection changes the control problem. A fixed check can be reviewed before execution, while an agent may propose a new sequence after reading a response. The buyer needs to know which actions are preapproved, which require a human decision and which are impossible because the execution environment blocks them. A prompt asking the model to be careful is not equivalent to an enforced boundary.

Ask for a diagram of data and authority flows. Identify the model service, orchestration layer, tool runner, credential store, target environment and evidence repository. For each connection, ask what information and permission cross it. This turns an abstract discussion about intelligence into a concrete assessment of operational exposure.

Classify target safety before discussing speed

Healthcare systems differ in their tolerance for active testing. A patient portal in an isolated test environment is not equivalent to a device supporting care delivery. Classify targets with service owners and clinical engineering before deciding which automation is appropriate. Unknown assets should remain outside active testing until ownership and constraints are resolved.

For each class, define permitted actions, rate limits, time windows, monitoring and stop conditions. The limits should be enforced where possible by the tool runner or network boundary, not left entirely to a model’s interpretation. The human assessment team remains responsible for ensuring the activity stays within the agreed scope and for responding to unexpected effects.

Ask how the provider handles a newly discovered host or integration. An agent should not treat discovery as permission to test. The workflow should record the observation and request a scope decision where required. That principle is particularly important when an ordinary business application connects to clinical services or vendor-operated infrastructure that was not included in the original authorisation.

Limit tool authority independently of model instructions

Review the actual tool permissions. Can the system only send bounded requests to approved endpoints, or can it execute arbitrary commands, change configuration, create accounts or access unrelated networks? Broad tool access increases the consequences of an incorrect decision. Grant the minimum capabilities needed for the planned assessment and separate read-oriented observation from state-changing actions.

The OWASP guidance on excessive agency discusses risk arising from excessive functionality, permissions and autonomy. For a testing service, apply that idea to the execution boundary: a model recommendation should not bypass target allowlists, privilege limits or approval requirements enforced outside the model.

Ask how credentials are provided and removed. Avoid giving an automated runner a broadly privileged account simply because it simplifies setup. Use scoped, attributable test identities with expiry where practical. The provider should explain whether credentials can enter model context or logs, how they are protected and how access is revoked after the engagement.

Understand where patient and system information goes

An agent may send responses, screenshots, logs or documents to a model service as context. Those materials can contain sensitive information even when the original test request was harmless. Ask the provider to document what is transmitted, where it is processed, how it is retained and which parties can access it. Do not assume that a local tool runner means all data remains local.

Prefer synthetic fixtures and minimise collected content. A test can often establish an authorisation failure using a clearly fictional record with a unique marker. That reduces unnecessary exposure while preserving evidence. If the assessment could encounter real information, agree a handling procedure before execution, including how the system stops or limits collection and how the human team reviews the event.

Treat prompts, intermediate outputs and traces as evidence-bearing records. They may contain target details, credentials or sensitive snippets. The retention and access plan should cover them as well as the final report. A vendor that secures the PDF but ignores the orchestration logs has not explained the full data-handling boundary.

Treat target content as observations, not instructions

A testing agent reads material from the system being assessed. That material may be attacker-controlled or simply contain text that looks like instructions. The agent should not be allowed to reinterpret page content, logs or documents as authority to change its scope, reveal secrets or invoke unrelated tools. The provider should explain how this trust boundary is handled.

Ask for a controlled evaluation of that boundary in a laboratory setting. For example, a harmless synthetic page can contain text attempting to redirect the agent to an out-of-scope destination. The expected result is that execution controls prevent the action and the trace records the rejected proposal. This is a test of the testing system, not permission to plant instructions in production clinical content.

Do not rely solely on the model saying it ignored the instruction. Review actual tool calls and enforcement events. A confident explanation can be inconsistent with the executed sequence. The buyer needs evidence that the runner stayed within scope, not merely a narrative describing intended behaviour.

Define the human review gates precisely

Human oversight is useful only when the reviewer has enough context and authority to make a meaningful decision. Specify which actions require approval, what information is shown and how approval is tied to the exact proposed operation. A generic approval at the beginning of the day should not silently authorise a later high-impact action with different targets or parameters.

The reviewer should see the target, purpose, expected effect, operational risk and relevant limits. For state-changing work, include the fixture and rollback or reconciliation plan. If the proposal changes after approval, the system should obtain a new decision where the change is material. Otherwise the approval record may not correspond to what actually ran.

Manage reviewer workload. Hundreds of repetitive prompts can produce mechanical approval and obscure the important decisions. Use bounded preapproval for well-defined low-risk actions and reserve explicit review for meaningful changes in authority or impact. Record rejected actions as well as approved ones; those records help assess whether the controls are working.

Compare coverage through the same test questions

A fair comparison uses the same application questions and evidence criteria for each approach. Define a small representative set of workflows, roles and boundaries. Include straightforward repeatable checks and cases that require understanding delegated access or state changes. Then examine which questions were answered, which remained uncertain and how much human effort was required to validate the result.

Do not compare raw request counts or findings counts as though they directly measure quality. More traffic can mean repetition, and more findings can mean duplicates or false positives. Useful measures include verified coverage of agreed conditions, reproducible findings, accurate limitations and time needed by engineers to understand the evidence.

Ask how the tool records untested areas. An agent may stop exploring after finding one issue or misinterpret a blocked route as complete coverage. A coverage register should show what was attempted and what evidence supports each conclusion. The final report should not convert unexplored areas into implicit passes.

Identify where human investigation adds necessary context

Healthcare workflows can depend on relationships that are not obvious from an interface: care-team membership, delegated authority, referral purpose and encounter state. A human assessor can ask the owner to clarify intended behaviour and adapt the test accordingly. An agent can assist with execution or organisation, but it should not invent the policy and then judge the system against that invention.

Manual work also needs structure. An experienced assessor can still miss a route, misunderstand a workflow or produce incomplete evidence. Require a coverage model, controlled fixtures and technical review regardless of how much AI is used. The comparison should not romanticise manual testing as inherently comprehensive; it should identify the tasks and decisions that require accountable human judgement.

A useful division of work may let automation repeat approved checks while the assessor investigates ambiguous relationships, validates findings and manages operational decisions. The exact balance should follow the target and risk. The provider should explain that balance in the proposal instead of presenting autonomy itself as the customer outcome.

Require independent validation of generated findings

A generated finding should be treated as a candidate until its evidence is reviewed. The reviewer should identify the actual request or action, the observed response or state change and the violated requirement. If the system only predicts a possible weakness, label it as a hypothesis requiring investigation. Do not publish speculative impact as a confirmed exploit.

Reproduce important findings with controlled fixtures where safe. Preserve the original trace and compare the repeated observation. The validation method should not depend solely on asking the same model whether its earlier conclusion was correct. Human review and independently inspectable evidence are especially important when the report will drive clinical or business decisions.

Check for invented details in generated prose. A report may accidentally introduce commands, timestamps, affected records or outcomes that do not appear in the evidence. The reviewer should verify those details before delivery. A polished paragraph is not a substitute for a traceable observation, and fictional narrative must never be presented as a real customer test.

Preserve enough execution context to review the result

Record the relevant tool versions, configuration, target release, test identities by safe label and executed sequence. For agent-assisted work, preserve the decisions and tool calls needed to understand the result. You do not need to publish every internal prompt in the final report, but the restricted evidence should support review of significant conclusions and scope compliance.

Model behaviour can vary, so distinguish repeatable target evidence from the path the agent happened to choose. A finding is stronger when another authorised reviewer can reproduce the underlying behaviour without requiring the same model to make the same sequence of decisions. The report should provide that reproducible technical core.

Version changes require attention. Updating a model, prompt, tool integration or permission configuration can change the testing system’s behaviour. Ask how the provider evaluates those changes before using them in a sensitive engagement. A successful demonstration of an older configuration does not automatically establish the controls of a newly deployed one.

Test the stop mechanism before relying on it

A stop button is meaningful only if it prevents further relevant actions. Ask what happens to queued jobs, active tool calls, retries and background processes when a stop is issued. Some operations may not be instantly reversible, so the plan should distinguish stopping new work from reconciling actions already in progress. The owner must understand that difference.

Demonstrate the stop procedure in an isolated environment using harmless actions. Confirm that the responsible person can invoke it, that execution stops within the expected boundary and that the event is recorded. Check whether restarting requires an explicit decision and whether the system retains the original scope. This small rehearsal is more useful than discovering the mechanism during an operational problem.

Define communication separately from tooling. The clinical or service owner needs a reliable way to reach the assessor, and the assessor needs a clear escalation contact. An automated runner should not continue simply because a message reached the wrong chat channel. The engagement plan should identify the authoritative stop signal and who monitors it.

Run a bounded pilot before broader adoption

A sensible pilot uses an isolated, representative application with synthetic data and no live clinical dependencies. Define a small set of permitted actions and evaluation questions. Include target-boundary enforcement, evidence quality, finding validation and stop behaviour. The pilot should evaluate the service’s controls as well as its ability to identify weaknesses.

Compare results against owner-confirmed expected behaviour and, where appropriate, a manually reviewed baseline. Do not seed dangerous conditions in production to create a benchmark. If a laboratory includes known weaknesses, keep it isolated and document that the results reflect that environment. Success in a deliberately vulnerable lab does not prove equal effectiveness against every real system.

At the end, record what the pilot supports and what remains unproven. You may conclude that the system is useful for repeatable authenticated checks but not approved for adaptive production testing. That is a valid outcome. Adoption can be scoped to demonstrated capabilities instead of treated as an all-or-nothing decision.

Worked example: a portal testing pilot

Imagine a fictional patient portal in a test environment with two synthetic patients and a time-limited caregiver relationship. The team permits bounded read-oriented requests and requires approval for state changes. The agent can propose tests and execute within the allowlisted environment, while a human assessor confirms the intended delegation rules and reviews candidate findings.

The pilot checks ordinary patient isolation, caregiver scope and expiry. It also introduces a harmless instruction-like string in a synthetic page to test whether the runner attempts to leave scope. The expected control is an independently enforced denial, not merely a model response saying it will behave. The team records the attempted and executed actions separately.

If the agent identifies a possible expiry gap, the assessor reproduces it with fresh fixtures and inspects the actual response. The final pilot report states the verified behaviour, the controls demonstrated and the limits of the test. It does not claim autonomous clinical safety or universal coverage. The organisation can then decide which bounded tasks, if any, to adopt.

Put the operating model in the contract

Require the provider to disclose material AI use, data-processing locations and the division of responsibility between automation and human assessors. Specify approved target classes, prohibited actions, review gates and evidence retention. Ask how changes to the testing system will be communicated during the engagement. These details should not remain informal assumptions.

Define deliverables in terms of verified coverage and actionable findings. Avoid buying only a number of agent runs or a promise of continuous intelligence. Ask how false positives are corrected, how disputed results are reviewed and how remediation is retested. The customer outcome is reliable evidence and useful decisions, not a particular amount of model activity.

Our healthcare vendor evaluation guide provides a broader scorecard. The delegated-access testing guide offers concrete application questions that can be used to compare proposed coverage. Keep the comparison tied to your actual environment and operational constraints.

Define an exit and access-removal plan

Before a pilot or engagement starts, agree how the testing service will be disconnected. Inventory its accounts, tokens, runners, network permissions and stored evidence. Assign an owner to remove each item and define how completion will be verified. A successful assessment should not leave behind an unowned automation account or an agent runner with access to the environment. Include subcontractor and model-processing arrangements in the evidence-retention decision where relevant.

At closure, reconcile the inventory with what was actually created during testing. Preserve the approved report and necessary evidence, remove temporary access and record any retained integration with a named business reason. If the organisation intends to continue using the tool, convert the temporary arrangement into an explicitly owned service with review dates and change controls. Continued use should be a deliberate operational decision, not an accidental consequence of a successful demonstration.

Choose accountable testing with explicit limits

The NIST generative AI risk profile provides governance context for human review and documentation. The OWASP AI Agent Security Cheat Sheet discusses tool permissions and execution safeguards. These references inform questions to ask; they do not certify a particular healthcare testing product.

Use the healthcare scoping brief to describe the application, target classes, data constraints and desired evidence. State whether AI processing is restricted by your organisation and whether a supplier must disclose its model and tool boundaries. Those requirements are easier to resolve before testing begins.

Contact Atlant Security to discuss an assessment with clear human accountability, controlled methods and evidence your team can review. The right approach may include automation, but its value should be demonstrated through the quality of the work and the decisions it supports.